Article
Author: Norris, Derek ; Williams, David ; Napoline, Jonathan ; Dhar, T. G. Murali ; Dai, Chao ; Nanjappa, Purushothama ; Mathur, Arvind ; Wichroski, Michael ; Naglich, Joseph ; Tokarski, John S. ; Gill, Patrice ; Venkatanarayan, Avinashnarayan ; Li, Ling ; Wong, Jessica ; Hafeji, Yamnah ; Fang, Hua ; Xu, Songmei ; Chourb, Lisa ; Zhang, Jun ; Soars, Matthew G. ; Gavai, Ashvinikumar V. ; Downes, Daniel P. ; Wang, Ying-Kai ; Locke, Gregory ; Barbieri, Christopher ; Tester, Richland ; Borzilleri, Robert M. ; Lees, Emma ; Jorge, Christine ; Qi, Huilin ; Yu, Fei ; Li, Yi-Xin ; Qiao, Jennifer X. ; Degnen, Bill
We describe the design, synthesis, and structure-activity relationship (SAR) of heterobifunctional RET ligand-directed degraders (LDDs) derived from three different second-generation RET inhibitors. These LDDs are composed of a target binding motif (TBM) that binds to the RET protein, a linker, and a cereblon binding motif (CBM) as the E3 ligase recognition unit. This led to the identification of a series of pyrazolopyridine-based heterobifunctional LDDs, as exemplified by compound 39. LDD 39 demonstrated high in vitro inhibitory and degradation potency against both RET wild-type and the two representative mutants, V804M and G810R. Importantly, in PK/PD studies, 39 exhibited a differentiated and favorable in vivo profile compared to the corresponding tyrosine kinase inhibitor (TKI), compound 3. Robust and sustained degradation of total-RET (tRET) protein and inhibition of phospho-RET (pRET) signaling were observed in TPC-1 xenograft tumors driven by RET and the RET/G810R mutant following a single dose of LDD 39 at 15 and 75 mg/kg, respectively.